MedPath

A Compassionate Use (CU) Program of Odronextamab

Conditions
Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Diffuse Large B-Cell Lymphoma (DLBCL)
B-Cell Non-Hodgkin Lymphoma (NHL)
High-Grade B-Cell Lymphoma (HGBCL)
Registration Number
NCT05619367
Lead Sponsor
Regeneron Pharmaceuticals
Brief Summary

Provide compassionate use of odronextamab

Detailed Description

Not available

Recruitment & Eligibility

Status
AVAILABLE
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath